midazolam has been researched along with Adverse Drug Event in 12 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Other procedural time parameters, satisfaction profiles, and adverse effects were thoroughly evaluated." | 3.30 | Safety and efficacy of remimazolam compared with midazolam during bronchoscopy: a single-center, randomized controlled study. ( Cho, JY; Choe, KH; Chung, JM; Han, JH; Kim, EG; Kim, M; Kim, SH; Lee, KM; Seok, JW; Seong, C; Shin, YM; Yang, B; Yang, J, 2023) |
| "Rifapentine (RP T) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RI F)." | 2.77 | Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. ( Bliven-Sizemore, EE; Burman, WJ; Dooley, KE; Dorman, SE; Fuchs, EJ; Hubbard, WC; Lu, Y; Melia, MT; Nuermberger, EL; Weiner, M, 2012) |
| "It has been proposed that objective cognitive testing provides additional information to that collected via adverse event (AE) recordings." | 2.72 | Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. ( Collie, A; Darekar, MA; Huggins, JP; Maruff, P; Snyder, PJ, 2006) |
| "Evaluate adverse events associated with oral midazolam as a perioperative anxiolytic during dermatologic surgery and assess whether an enhanced monitoring approach is associated with an increased detection rate." | 1.56 | Safety of Oral Midazolam as a Perioperative Anxiolytic for Outpatient Dermatologic Procedures. ( Arpey, CJ; Baum, CL; Bezalel, SA; Brewer, JD; Otley, CC; Roenigk, RK, 2020) |
| "Propofol is an addictive drug, and the problem of its abuse and dependence has occurred." | 1.42 | Increased use in propofol and reported patterns of adverse events among anesthetics in Korea. ( Kim, MH; Park, BJ; Park, HJ; Shin, JY, 2015) |
| " We calculated rates of adverse events according to benzodiazepine use and identified risk factors for complications using univariate and multivariate analyses." | 1.39 | Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy. ( Arpino, P; Backman, ES; Ehrenfeld, JM; Gandhi, RT; Losina, E; Lu, Z; Triant, VA, 2013) |
| "To compare the occurrence of post-discharge adverse events in children having received a high dose of either chloral hydrate (CH) or midazolam (MZ) during outpatient dental treatment." | 1.38 | Post-discharge adverse events following pediatric sedation with high doses of oral medication. ( Bendo, CB; Brasileiro, SV; Costa, LR; Costa, PS; Paiva, SM; Viegas, CM, 2012) |
| "57% of patients having complications (52 patients having 60 adverse events)." | 1.37 | Safety of intravenous sedation administered by the operating oral surgeon: the second 7 years of office practice. ( Rodgers, MS; Rodgers, SF, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Mohan, AM | 1 |
| Sharma, A | 1 |
| Goyal, S | 1 |
| Kothari, N | 1 |
| Vyas, R | 1 |
| Goel, AD | 1 |
| Sethi, P | 1 |
| Kumari, K | 1 |
| Bhatia, P | 1 |
| Kim, SH | 1 |
| Cho, JY | 1 |
| Kim, M | 1 |
| Chung, JM | 1 |
| Yang, J | 1 |
| Seong, C | 1 |
| Kim, EG | 1 |
| Seok, JW | 1 |
| Shin, YM | 1 |
| Lee, KM | 1 |
| Choe, KH | 1 |
| Han, JH | 1 |
| Yang, B | 1 |
| Bezalel, SA | 1 |
| Brewer, JD | 1 |
| Baum, CL | 1 |
| Arpey, CJ | 1 |
| Roenigk, RK | 1 |
| Otley, CC | 1 |
| Park, HJ | 1 |
| Shin, JY | 1 |
| Kim, MH | 1 |
| Park, BJ | 1 |
| Rodgers, SF | 1 |
| Rodgers, MS | 1 |
| Costa, LR | 1 |
| Costa, PS | 1 |
| Brasileiro, SV | 1 |
| Bendo, CB | 1 |
| Viegas, CM | 1 |
| Paiva, SM | 1 |
| Dooley, KE | 1 |
| Bliven-Sizemore, EE | 1 |
| Weiner, M | 1 |
| Lu, Y | 1 |
| Nuermberger, EL | 1 |
| Hubbard, WC | 1 |
| Fuchs, EJ | 1 |
| Melia, MT | 1 |
| Burman, WJ | 1 |
| Dorman, SE | 1 |
| Backman, ES | 1 |
| Triant, VA | 1 |
| Ehrenfeld, JM | 1 |
| Lu, Z | 1 |
| Arpino, P | 1 |
| Losina, E | 1 |
| Gandhi, RT | 1 |
| Collie, A | 1 |
| Maruff, P | 1 |
| Snyder, PJ | 1 |
| Darekar, MA | 1 |
| Huggins, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling[NCT02563327] | Phase 3 | 60 participants (Anticipated) | Interventional | 2016-05-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for midazolam and Adverse Drug Event
| Article | Year |
|---|---|
Comparison of Caudal Dexmedetomidine and Midazolam as an Adjuvant to Ropivacaine for Postoperative Pain Relief in Children Undergoing Infra-Umbilical Surgeries: A Randomized Controlled Trial.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Agnosia; Child; Child, Preschool; Dexmedetomidine; | 2023 |
Safety and efficacy of remimazolam compared with midazolam during bronchoscopy: a single-center, randomized controlled study.
Topics: Benzodiazepines; Bronchoscopy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; | 2023 |
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
Topics: Adult; Antitubercular Agents; Area Under Curve; Cytochrome P-450 CYP3A; Drug-Related Side Effects an | 2012 |
Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study.
Topics: Adolescent; Adult; Clinical Trials, Phase I as Topic; Cognition; Cross-Over Studies; Dose-Response R | 2006 |
8 other studies available for midazolam and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Safety of Oral Midazolam as a Perioperative Anxiolytic for Outpatient Dermatologic Procedures.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; An | 2020 |
Increased use in propofol and reported patterns of adverse events among anesthetics in Korea.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anesthetics, Intravenous; Child; C | 2015 |
Safety of intravenous sedation administered by the operating oral surgeon: the second 7 years of office practice.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Dental; Anesthetics, Intravenous; Conscious | 2011 |
Post-discharge adverse events following pediatric sedation with high doses of oral medication.
Topics: Administration, Oral; Ambulatory Care; Anesthesia, Dental; Child; Child, Preschool; Chloral Hydrate; | 2012 |
Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy.
Topics: Adult; Anesthetics, Intravenous; Colonoscopy; Diazepam; Drug-Related Side Effects and Adverse Reacti | 2013 |